Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Concord Biotech Limited

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.

The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

Rising Tide

Quadria Capital

Neuberger Berman

Critically ill patients on ventilators face a high risk of lower respiratory tract infections, such as ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). VAP is linked to increased morbidity and mortality in the ICU, emphasizing the need for prevention. 

This review examines the potential of pre-emptive aerosolized antibiotics (AA) in preventing ventilator-associated infections and whether aerosolized treatment for VAT can halt its progression to VAP. 

Read more: https://lnkd.in/dX6msByM 

#respiratoryinfections #ventilatorassociatedpneumonia #aerosolizedantibiotics #ventilatorassociatedtracheobronchitis #criticalcare #intensivecare

Concord Biotech stands united on World AIDS Day, spreading awareness and knowledge to foster a world free from HIV/AIDS. Together, let's strive for prevention, support, and a brighter, healthier future for all.

#WorldAIDSDAY2023
#WorldAIDSDay  #HIV #AIDS #HIVawareness #AIDSawareness

Tune in to today's episode of Good Health Conquest as we discuss the Role of the granzyme family in rheumatoid arthritis. Our spotlight turns to the granzyme family, specifically granzymes A, B, M, K, and the enigmatic granzyme H, shedding light on their potential role in rheumatoid arthritis pathogenesis.

Listen now: https://lnkd.in/d5UCpmhA
For more information, visit www.conquest.health

#RA #Rheumatoidarthritis #Granzyme #pathogenesis #podcast #Concordbiotech #GoodHealthConquest

On this Gurupurab, may the teachings of Guru Nanak Dev Ji inspire you to lead a life of compassion and righteousness. Happy Gurupurab!

#HappyGurupurab #Gurupurab #GuruNanakJayanti #HappyGuruNanakJayanti #ConcordBiotech

On today's episode of the Good Health Conquest, we discuss the Current Therapies in Kidney Transplant Rejection, specifically acute T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR). Stay tuned as we navigate the evolving landscape of kidney transplantation, striving for improved long-term outcomes and a deeper understanding of rejection mechanisms.

Listen now: https://lnkd.in/dU-xVv2q Find us on all major listening platforms and apps. For more information, visit our website at www.conquest.health

#kidneytransplant #renaltransplant #treansplantrejection #rejection #posttransplant #kidneycomplications #Concordbiotech

While there are chances to enhance antibiotic prescribing throughout the care spectrum, the discharge phase from hospitalization is a notable contributor to antibiotic overuse. 

Thus, it becomes imperative to improve antibiotic prescribing by optimizing antibiotic selection, reassessing antibiotic treatment, and using the shortest effective duration of therapy post-discharge.  

#Antibioticresistance #AntimicrobialAwarenessWeek #AntimicrobialResistance #WorldAntimicrobialAwarenessWeek #WAAW #WAAW2023 #AMR

	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
revenue	4.98B -	6.04B 21.25%	7.08B 17.28%	8.31B 17.25%	10.17B 22.43%
cost of revenue	1.37B -	1.20B 12.46%	1.78B 47.87%	1.97B 10.76%	4.06B 105.94%
gross profit	3.61B -	4.84B 34.10%	5.31B 9.67%	6.34B 19.42%	6.11B 3.55%
selling and marketing expenses	156.03M -	133.63M 14.36%	214.36M 60.41%	236.98M 10.55%
general and administrative expenses	63.01M -	70.94M 12.59%	105.81M 49.15%	105.02M 0.75%
selling general and administrative expenses	219.04M -	204.57M 6.61%	320.17M 56.51%	342M 6.82%	2.33B 581.69%
research and development expenses	157.76M -	192.91M 22.28%	258.47M 33.98%	277.59M 7.40%	209.84M 24.41%
other expenses	2.85M -	11.25M 294.74%	9.73M 13.51%	62.04M 537.62%	337.80M 444.49%
cost and expenses	3.04B -	3.01B 0.90%	4.72B 57.02%	5.26B 11.34%	6.39B 21.50%
operating expenses	1.66B -	1.80B 8.66%	2.94B 63.12%	3.29B 11.70%	2.33B 29.10%
interest expense	6.99M -	6.66M 4.72%	54.84M 723.42%	45.11M 17.74%	25.52M 43.43%
ebitda	2.23B -	3.34B 49.73%	2.94B 12.08%	3.76B 27.99%	4.32B 14.68%
operating income	1.83B -	2.93B 59.98%	2.24B 23.48%	2.79B 24.35%	3.78B 35.54%
depreciation and amortization	212.45M -	275.23M 29.55%	500.50M 81.85%	540.33M 7.96%	167.90K 99.97%
total other income expenses net	302.61M -	185.27M 38.77%	121.12M 34.63%	367.54M 203.45%	312.28M 15.04%
income before tax	2.14B -	3.13B 46.38%	2.38B 24.05%	3.22B 35.57%	4.09B 27.07%
income tax expense	445.26M -	778.33M 74.80%	625.89M 19.59%	819.28M 30.90%	1.04B 27.50%
net income	1.69B -	2.35B 38.89%	1.75B 25.53%	2.40B 37.25%	3.08B 28.33%
weighted average shs out	104.62M -	104.62M 0%	104.62M 0%	104.62M 0%	104.62M 0%
weighted average shs out dil	104.62M -	104.62M 0%	104.62M 0%	104.62M 0%	104.62M 0%
eps	16.17 -	22.45 38.84%	16.72 25.52%	22.95 37.26%	29.45 28.32%
epsdiluted	16.17 -	22.45 38.84%	16.72 25.52%	22.95 37.26%	29.45 28.32%

CONC

COM:CONCORDBIOTECH

Concord Biotech

Last Close

2,031.55

25/11 09:20

Market Cap

176.73B

Beta: -

Volume Today

7.43K

Avg: -

Preview